Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

NCT03058289 is registered in ClinicalTrials.gov with Intensity Therapeutics, Inc. as lead sponsor.

NCT NCT03058289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03058289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
Lead sponsor
Intensity Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 9, 2017
Completion date
February 22, 2023
Enrollment
111 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, breast cancer, chordoma of sacrum, colon cancer, head and neck cancer, liver cancer, lung cancer, lymphoma, pancreatic cancer, sarcoma, squamous cell carcinoma